Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: Experimental study of mouse and human arteries

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 12, 2006, Pages 1461-1467

  Laitinen, Iina ^a   Marjamäki, Päivi ^a   Haaparanta, Merja ^a   Savisto, Nina ^a   Laine, V Jukka O ^b   Soini, Sanna L ^a   Wilson, Ian ^c   Leppänen, Pia ^d   Ylä Herttuala, Seppo ^d   Roivainen, Anne ^a   Knuuti, Juhani ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c GE HEALTHCARE   (United Kingdom)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

18F FDG; Atherosclerosis; Calcification; PET; Plaque

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTORADIOGRAPHY; CAROTID ARTERY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; FEMORAL ARTERY; HISTOLOGY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION;

ANIMALS; AORTA; APOLIPOPROTEIN B-48; ARTERIES; ATHEROSCLEROSIS; AUTORADIOGRAPHY; CALCINOSIS; CAROTID STENOSIS; FEMORAL ARTERY; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; TISSUE DISTRIBUTION;

EID: 33845351241     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0159-6     Document Type: Article

References (14)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-3488
2. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245-1250
3. 18F]- fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-2711
4. Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48- only" and "Apo-B100-only" mice. J Clin Invest 1998;102:1559-1568
5. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238
6. 18F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278-1284
7. 18F-FDG PET/CT. J Nucl Med 2004;45:1816-1821
8. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004;25:629-672
9. Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998;4:934-938
10. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000;106:1501-1510
11. Leppänen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005;112:1347-1352
12. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503-517
13. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002;16:577-582
14. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285-290